Sponsors (2)
The bill aims to lower prices and boost competition by restricting vertical ownership and strengthening enforcement, but does so at the risk of care disruptions, higher short-term costs, and greater regulatory and litigation burdens that could be passed on to patients and taxpayers.
Patients (including those with chronic conditions and Medicare beneficiaries) could pay lower drug and care prices and face fewer conflicts of interest as vertical ties between insurers/PBMs/wholesalers and providers are broken, increasing competition.
Medicare beneficiaries and taxpayers could see reduced inflated Medicare Advantage payments if practices that raise documented payments through employed-physician arrangements are curtailed.
Independent physician practices and smaller providers may regain market share and bargaining power as insurers and wholesalers divest provider holdings, supporting provider competition and potentially local access.
Patients (especially those with chronic conditions and Medicare beneficiaries) face risk of disrupted care continuity and reduced care coordination if rapid forced breakups or dismantling of integrated entities interrupt operations or clinical relationships.
Insured individuals and taxpayers could ultimately pay higher prices if companies pass divestiture, compliance, restructuring, or enforcement-related costs onto consumers or if escrow/penalty regimes materially raise business costs.
Expanded FTC/DOJ authority combined with broader private litigation (including treble damages) will raise regulatory and litigation burdens and transaction uncertainty for health-sector firms, potentially slowing investment and complicating mergers.
Based on analysis of 3 sections of legislative text.
Bans combined ownership of providers/MSOs with insurers+PBMs or with wholesalers and requires divestiture within one year, enforced by FTC/DOJ with penalties and trustee sales.
Official title: Prohibit pharmacy benefit managers, insurers, and prescription drug or medical device wholesalers from being under common ownership with certain medical service providers, and for other purposes.
Introduced February 10, 2026 by Elizabeth Warren · Last progress February 10, 2026
Makes it illegal for a single company to simultaneously own or control health care providers/MSOs and either (a) an insurer plus a pharmacy benefit manager (PBM) or (b) a drug/medical device wholesaler. Companies found in violation must divest one side of the business within one year of enactment, subject to FTC and DOJ enforcement, civil penalties, trustee sales, and escrowed profit transfers for missed milestones. The bill directs the FTC and DOJ to issue guidance, enables federal, state, and private civil suits, and creates mechanisms to enforce divestitures and recover proceeds if companies fail to comply.